과제정보
This work was supported by the Basic Science Research Program NRF-2021R1C1C1008780 to J.M.L., 2020R1I1A3072234 to J-S.L., and 2021R1I1A1A01057137 to J.K. from the National Research Foundation (NRF) grant funded by the Korea government.
참고문헌
- Li Y, Song Y and Liu S (2022) The new insight of treatment in Cholangiocarcinoma. J Cancer 13, 450-464 https://doi.org/10.7150/jca.68264
- Rizvi S and Gores GJ (2013) Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145, 1215-1229 https://doi.org/10.1053/j.gastro.2013.10.013
- Blechacz B, Komuta M, Roskams T and Gores GJ (2011) Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 8, 512-522 https://doi.org/10.1038/nrgastro.2011.131
- Banales JM, Marin JJ, Lamarca A et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17, 557-588 https://doi.org/10.1038/s41575-020-0310-z
- DeOliveira ML, Cunningham SC, Cameron JL et al (2007) Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 245, 755-762 https://doi.org/10.1097/01.sla.0000251366.62632.d3
- Ramirez-Merino N, Aix SP and Cortes-Funes H (2013) Chemotherapy for cholangiocarcinoma: an update. World J Gastrointest Oncol 5, 171-176 https://doi.org/10.4251/wjgo.v5.i7.171
- Goyal L, Kongpetch S, Crolley VE and Bridgewater J (2021) Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev 95, 102170
- Massironi S, Pilla L, Elvevi A et al (2020) New and emerging systemic therapeutic options for advanced cholangiocarcinoma. Cells 9, 688
- Kroemer G, Marino G and Levine B (2010) Autophagy and the integrated stress response. Mol Cell 40, 280-293 https://doi.org/10.1016/j.molcel.2010.09.023
- Yonekawa T and Thorburn A (2013) Autophagy and cell death. Essays Biochem 55, 105-117 https://doi.org/10.1042/bse0550105
- Chavez-Dominguez R, Perez-Medina M, Lopez-Gonzalez JS, Galicia-Velasco M and Aguilar-Cazares D (2020) The double-edge sword of autophagy in cancer: from tumor suppression to pro-tumor activity. Front Oncol 10, 578418
- Maiuri M, Tasdemir E, Criollo A et al (2009) Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ 16, 87-93 https://doi.org/10.1038/cdd.2008.131
- Liberti MV and Locasale JW (2016) The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 41, 211-218 https://doi.org/10.1016/j.tibs.2015.12.001
- Hanahan D and Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674 https://doi.org/10.1016/j.cell.2011.02.013
- Wang Z, Liu F, Fan N et al (2020) Targeting glutaminolysis: new perspectives to understand cancer development and novel strategies for potential target therapies. Front Oncol 10, 589508
- Yoo HC, Yu YC, Sung Y and Han JM (2020) Glutamine reliance in cell metabolism. Exp Mol Med 52, 1496-1516 https://doi.org/10.1038/s12276-020-00504-8
- Yu D, Shi X, Meng G et al (2015) Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma. Oncotarget 6, 7619
- Simpson NE, Tryndyak VP, Beland FA and Pogribny IP (2012) An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression. Breast Cancer Res Treat 133, 959-968 https://doi.org/10.1007/s10549-011-1871-x
- Liu HY, Zhang HS, Liu MY, Li HM, Wang XY and Wang M (2021) GLS1 depletion inhibited colorectal cancer proliferation and migration via redox/Nrf2/autophagy-dependent pathway. Arch Biochem Biophys 708, 108964
- Lee SY, Jeon HM, Ju MK et al (2016) Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch. Oncotarget 7, 7925-7939 https://doi.org/10.18632/oncotarget.6879
- Nieto MA, Huang RY, Jackson RA and Thiery JP (2016) EMT: 2016. Cell 166, 21-45 https://doi.org/10.1016/j.cell.2016.06.028
- Huang F, Wang BR and Wang YG (2018) Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma. World J Gastroenterol 24, 4643
- Cao J, Zhang C, Jiang GQ et al (2019) Expression of GLS1 in intrahepatic cholangiocarcinoma and its clinical significance. Mol Med Rep 20, 1915-1924 https://doi.org/10.3892/mmr.2019.10399
- Altevogt P, Ben-Ze'ev A, Gavert N, Schumacher U, Schafer H and Sebens S (2020) Recent insights into the role of L1CAM in cancer initiation and progression. Int J Cancer 147, 3292-3296 https://doi.org/10.1002/ijc.33177
- Fardi M, Alivand M, Baradaran B, Farshdousti Hagh M and Solali S (2019) The crucial role of ZEB2: from development to epithelial-to-mesenchymal transition and cancer complexity. J Cell Physiol 234, 14783-14799 https://doi.org/10.1002/jcp.28277
- Rankin EB and Giaccia AJ (2016) The receptor tyrosine kinase AXL in cancer progression. Cancers (Basel) 8, 103
- Mookerjee SA, Nicholls DG and Brand MD (2016) Determining maximum glycolytic capacity using extracellular flux measurements. PLoS One 11, e0152016
- Sagot I and Laporte D (2019) The cell biology of quiescent yeast - a diversity of individual scenarios. J Cell Sci 132, jcs213025
- Liu Y, Zhang W, Cao Y, Liu Y, Bergmeier S and Chen X (2010) Small compound inhibitors of basal glucose transport inhibit cell proliferation and induce apoptosis in cancer cells via glucose-deprivation-like mechanisms. Cancer letters 298, 176-185 https://doi.org/10.1016/j.canlet.2010.07.002
- Zhang TB, Zhao Y, Tong ZX and Guan YF (2015) Inhibition of glucose-transporter 1 (GLUT-1) expression reversed Warburg effect in gastric cancer cell MKN45. Int J Clin Exp Med 8, 2423
- Oh S, Kim H, Nam K and Shin l (2017) Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triplenegative breast cancer cells. BMB Rep 50, 132-137 https://doi.org/10.5483/BMBRep.2017.50.3.189
- Englinger B, Pirker C, Heffeter P et al (2018) Metal drugs and the anticancer immune response. Chem Rev 119, 1519-1624 https://doi.org/10.1021/acs.chemrev.8b00396
- Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH and Hodi FS (2013) Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measure-mentsunidimensional irRC as a common language for immunotherapy. Clin Cancer Res 19, 3936-3943 https://doi.org/10.1158/1078-0432.CCR-13-0895
- Carbone DP, Reck M, Paz-Ares L et al (2017) First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376, 2415-2426 https://doi.org/10.1056/NEJMoa1613493
- Wang L, Zhao X, Fu J, Xu W and Yuan J (2021) The role of tumour metabolism in cisplatin resistance. Front Mol Biosci 8, 691795
- Yoshida GJ (2015) Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res 34, 1-10 https://doi.org/10.1186/s13046-015-0221-y
- Klepper J, Vera JC and De Vivo DC (1998) Deficient transport of dehydroascorbic acid in the glucose transporter protein syndrome. Ann Neurol 44, 286-287 https://doi.org/10.1002/ana.410440225
- Reckzeh ES, Karageorgis G, Schwalfenberg M et al (2019) Inhibition of glucose transporters and glutaminase synergistically impairs tumor cell growth. Cell Chem Biol 26, 1214-1228 e1225